Baird analyst Catherine Ramsey Schulte raised the firm’s price target on Twist Bioscience (TWST) to $54 from $48 and keeps an Outperform rating on the shares. The firm said Q1 results beat expectations and saw encouraging gross margins progress.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST: